Fulvestrant - EVER Pharma

Dosage Form	Solution for injection in pre-filled syringe
Strength	250 mg
Strength per Unit	250 mg/5 ml
ATC Code	L02BA03
Drug Class	Endocrine therapy
Indication	Fulvestrant EVER Pharma in indicated: as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: – not previously treated with endocrine therapy, or – with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy (see section 5.1). In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.

Fulvestrant EVER Pharma is a prescription medication. Information for healthcare professionals only.
See the Summary of Product Characteristics for full information about the medication.